Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
$50.51
-2.5%
$51.56
$21.34
$58.40
$4.13B-0.151.14 million shs1.01 million shs
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
$11.25
+1.6%
$9.54
$6.38
$17.30
$1.07B1.421.17 million shs779,902 shs
Metsera Inc. stock logo
MTSR
Metsera
$39.65
-0.9%
$31.62
$12.30
$47.40
$4.20BN/A748,635 shs752,750 shs
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
$33.21
-2.1%
$31.34
$21.51
$56.00
$4.09B0.912.03 million shs916,676 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
-0.12%-3.32%-4.09%+26.42%+86.47%
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
-1.42%+3.94%+16.04%+28.72%-31.88%
Metsera Inc. stock logo
MTSR
Metsera
+1.37%-8.55%+37.90%+88.81%+3,998,999,900.00%
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
+1.16%+1.16%+16.36%+9.67%-26.20%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
3.796 of 5 stars
3.51.00.04.73.50.80.0
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
2.0841 of 5 stars
3.51.00.00.02.01.70.6
Metsera Inc. stock logo
MTSR
Metsera
N/AN/AN/AN/AN/AN/AN/AN/A
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
2.4518 of 5 stars
4.50.00.00.03.30.80.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
3.00
Buy$82.5063.33% Upside
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
3.00
Buy$18.3362.96% Upside
Metsera Inc. stock logo
MTSR
Metsera
3.00
Buy$55.0038.71% Upside
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
3.06
Buy$66.3599.80% Upside

Current Analyst Ratings Breakdown

Latest AVDL, MTSR, RNA, and AKRO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/18/2025
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$22.00
7/11/2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$70.00
7/10/2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$55.00
6/27/2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$96.00
6/24/2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$50.00
6/20/2025
Metsera Inc. stock logo
MTSR
Metsera
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$65.00
6/17/2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$55.00
6/11/2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageStrong-Buy$65.00
6/10/2025
Metsera Inc. stock logo
MTSR
Metsera
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$56.00 ➝ $62.00
6/10/2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$70.00 ➝ $75.00
6/10/2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$57.00 ➝ $59.00
(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
N/AN/AN/AN/A$10.75 per shareN/A
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
$169.12M6.44N/AN/A$0.77 per share14.61
Metsera Inc. stock logo
MTSR
Metsera
N/AN/AN/AN/A($2.46) per shareN/A
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
$10.90M367.20N/AN/A$11.94 per share2.78
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
-$252.06M-$1.95N/AN/AN/AN/A-15.19%-13.97%8/8/2025 (Estimated)
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
-$48.83M-$0.27N/A187.50N/A-13.58%-36.07%-16.30%8/6/2025 (Estimated)
Metsera Inc. stock logo
MTSR
Metsera
-$209.13MN/A0.00N/AN/AN/AN/AN/A
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
-$322.30M-$3.00N/AN/AN/A-4,136.00%-26.96%-24.57%8/8/2025 (Estimated)

Latest AVDL, MTSR, RNA, and AKRO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
$0.02N/AN/AN/AN/AN/A
8/8/2025Q2 2025
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
-$0.95N/AN/AN/AN/AN/A
8/8/2025Q2 2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
-$0.93N/AN/AN/A$1.61 millionN/A
5/12/2025Q1 2025
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
-$1.01$0.90+$1.91$0.90N/AN/A
5/12/2025Q1 2025
Metsera Inc. stock logo
MTSR
Metsera
N/A-$1.03N/A-$1.03N/AN/A
5/8/2025Q1 2025
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
-$0.88-$0.90-$0.02-$0.90$2.63 million$1.60 million
5/7/2025Q1 2025
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
-$0.07-$0.05+$0.02-$0.05$50.57 million$52.51 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
N/AN/AN/AN/AN/A
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
N/AN/AN/AN/AN/A
Metsera Inc. stock logo
MTSR
Metsera
N/AN/AN/AN/AN/A
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
0.03
16.80
16.80
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
N/A
2.73
2.33
Metsera Inc. stock logo
MTSR
Metsera
N/A
6.55
6.55
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
N/A
16.91
16.91

Institutional Ownership

CompanyInstitutional Ownership
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
N/A
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
69.19%
Metsera Inc. stock logo
MTSR
Metsera
N/A
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
N/A

Insider Ownership

CompanyInsider Ownership
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
7.07%
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
5.20%
Metsera Inc. stock logo
MTSR
Metsera
N/A
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
3.83%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
3079.72 million74.08 millionOptionable
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
7096.74 million91.71 millionOptionable
Metsera Inc. stock logo
MTSR
Metsera
81105.06 millionN/AN/A
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
190120.52 million115.90 millionOptionable

Recent News About These Companies

Avidity granted FDA Breakthrough status for DMD therapy
Avidity Biosciences, Inc. (RNA) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Akero Therapeutics stock logo

Akero Therapeutics NASDAQ:AKRO

$50.51 -1.31 (-2.53%)
Closing price 04:00 PM Eastern
Extended Trading
$50.01 -0.50 (-0.99%)
As of 06:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Avadel Pharmaceuticals stock logo

Avadel Pharmaceuticals NASDAQ:AVDL

$11.25 +0.18 (+1.63%)
Closing price 04:00 PM Eastern
Extended Trading
$11.24 -0.01 (-0.04%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Metsera stock logo

Metsera NASDAQ:MTSR

$39.65 -0.34 (-0.85%)
As of 04:00 PM Eastern

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.

Avidity Biosciences stock logo

Avidity Biosciences NASDAQ:RNA

$33.21 -0.71 (-2.09%)
Closing price 04:00 PM Eastern
Extended Trading
$33.34 +0.13 (+0.38%)
As of 07:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.